Skip to main content
Premium Trial:

Request an Annual Quote

Bristol Myers-Squibb, Saladax Expand Companion Dx Deal to Include Ortho-Clinical Diagnostics

NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

The three firms will collaborate to develop and gain regulatory approval of certain diagnostic assays. Saladax and Ortho-Clinical have a separate agreement to commercialize assays resulting from the deal.

Financial and other terms of both deals were not disclosed.

Saladax and Bristol-Myers Squibb originally reached a partnership in May 2010 to develop clinical diagnostic tests for certain drug compounds in Bristol Myers-Squibb's pipeline. The terms of that deal called for the two firms to collaborate on development and regulatory approvals.

Saladax had exclusive global rights to commercialize assays developed from the collaboration.